PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Aspect Pharmaceuticals, LLC	08/03/2009

RECEIVING PARTY DATA

Name:	Vicept Therapeutics, Inc.			
Street Address:	101 Lindenwood Drive			
Internal Address:	Suite 130			
City:	Malvern			
State/Country:	PENNSYLVANIA			
Postal Code:	19355			

PROPERTY NUMBERS Total: 3

Property Type	Number		
Application Number:	10763807		
Application Number:	12272253		
PCT Number:	US0883774		

CORRESPONDENCE DATA

Fax Number: (412)281-0717

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 412-454-5000

Email: docketingpgh@pepperlaw.com

Correspondent Name: Pepper Hamilton LLP
Address Line 1: 500 Grant Street, 50th Floor

Address Line 2: One Mellon Center

Address Line 4: Pittsburgh, PENNSYLVANIA 15219

ATTORNEY DOCKET NUMBER: 136519.00101

NAME OF SUBMITTER: N. Nicole Endejann

PATENT

REEL: 023408 FRAME: 0935

OF \$120.00 10/6380

500995200

Total Attachments: 3

source=Assignment - Aspect to Vicept#page1.tif source=Assignment - Aspect to Vicept#page2.tif source=Assignment - Aspect to Vicept#page3.tif

> PATENT REEL: 023408 FRAME: 0936

EXHIBIT A

FORM OF RECORDATION DOCUMENT

SHORT-FORM PATENT ASSIGNMENT

[Aspect Pharmaceuticals, LLC, a Delaware limited liability company] ("ASSIGNOR") was heretofore the owner of the entire right, title and interest in the patent applications referred to in Exhibit A to this Short-Form Patent Assignment ("Assigned Families").

By prior assignment pursuant to that certain Assignment and License Agreement executed between ASSIGNOR and Therapeutics, Inc., a Delaware corporation with its principal place of business at Solve PA 19355 ("VICEPT") effective 2009, ASSIGNOR transferred, assigned and conveyed to VICEPT, the entire right, title, and interest in and to the Assigned Families and Letters Patent that may be issued on any of the Assigned Families in the United States, Australia, Japan, the countries in the European Organisation, and everywhere else in the world.

NOW, THEREFORE, ASSIGNOR hereby acknowledges that, consideration of the foregoing and the good and valuable consideration, the receipt and sufficiency of which is hereby forth in Assignment acknowledged, set such and Agreement, ASSIGNOR has heretofore transferred, assigned and conveyed to VICEPT all right, title and interest in and to the Assigned Families and Letters Patent that may be issued on any of the Assigned Families in the United States, Australia, Canada. countries in Japan, the the European Patent Organisation, and everywhere else in the world.

[CONTINUES ON NEXT PAGE]

2.

ASSIGNOR authorizes and requests the Commissioner of Patents and Trademarks of the United States and of Australia, European Canada. Japan, the countries in the Organisation, and anywhere else in the world to issue Letters Patent granted on the Assigned Families, whether on any subsequently filed division, continuation, continuation-in-part, reexamination, or reissue application, to VICEPT, its successors and assigns, as the assignee of the entire interest in the Assigned Families.

TESTIMONY WHEREOF, the undersigned has executed this instrument on the 3 day of August

ASPECZ PHARMACEUTICALS, L/LC

Name: STUART

Title: PRESIDENT + CEO ASPECT PHARMACEUTICALS

County of a

On 8/3/09 before me,

personally appeared

☐ personally known to me - OŔ- ☐ proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.

ALINA CAPUTO NOTARY PUBLIC OF NEW JERSEY

COMMISSION EXPIRES

EXHIBIT A TO SHORT-FORM PATENT ASSIGNMENT

Anniel and a second	HUNG DATE	PATENT	INT.	IIILE (OENIRS STATES
10/763,807	01/22/2004		,	Method and Therapeutic/Cosmetic U.S. Pending
				Topical Compositions for the
				Treatment of Rosacea and Skin
				Erythema Using α ₁ Adrenoreceptor
				Agonists
60/988,564	11/16/2007			Compositions and Methods for U.S. Expired
				Treating Purpura
12/272,253	11/17/2008			Compositions and Methods of U.S. Pending
				Treating Purpura
PCT/US08/0837	11/17/2008			Compositions and Methods of PCT Pending
74				Treating Purpura

4.

sf-2682168

RECORDED: 10/22/2009

PATENT REEL: 023408 FRAME: 0939